Barry Clare, Chairman
Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry and an experienced non-executive director and company chair. He is currently Deputy Chair of Manchester University Hospitals NHS Foundation Trust. Barry has held a number of senior roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare businesses, retail consumer products and in the financial sector. Barry created Boots Healthcare International, the international ‘over the counter’ consumer healthcare business of the Boots Company PLC.
Roger Hinton, Managing Director
Dr Roger Hinton has over 30 years’ experience within the pharmaceutical industry both at the operational and management level and has worked in research, product and process development and business development. Dr Hinton has a B. Sc. (Hons) in Microbiology and Ph.D. in microbial enzymology. He was formerly the PHE Head of Development and Production and is now the Managing Director of Porton Biopharma Limited and a member of the PBL board.
Richard Gleave (Non-Executive Director)
Richard Gleave is the Deputy Chief Executive and Chief Operating Officer of Public Health England and is one of the two “stakeholder” members of the Porton Biopharma Board. He has worked for the Department of Health, NHS South of England and a range of NHS hospitals in a range of senior roles.
Donald Shepherd (Non-Executive Director)
Donald Shepherd is the Finance and Commercial Director at PHE and is responsible for finance, estates, procurement, business development, ICT and Digital services as well as being one of the two “stakeholder” members of the Porton Biopharma Board.
Before joining PHE, Donald has held various senior finance positions within the NHS after starting his accountancy career in an audit and accountancy practice. Donald holds a BA (Hons) in Economics and Accountancy and is a fellow of the Association of Chartered Certified Accountants.
Rebecca Wilson (Non-Executive Director)
Rebecca is a Senior Commercial Specialist at the Department of Health and Social Care. She is a corporate finance lawyer by background and has been advising government for almost 20 years.
Rebecca has been providing commercial expertise to PBL since incorporation working closely with the Board. She has advised on the set up of most of the Department’s companies including Bio Products Laboratory and has led on a variety of complex commercial and infrastructure projects.
Bruce Pritchard (Non-Executive Director)
Bruce is the Chief Operating Officer- International of Liminal BioSciences Inc. As COO- International, Bruce oversees the company’s programme management, commercial, strategy, marketing, manufacturing, supply chain and business development functions.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than thirteen years’ experience with Liminal and has held a number of senior global positions across the organisation. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company.
Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland, where his is currently Deputy President, and a Fellow of the Institute of Directors. He is an experienced Trustee, non-executive director and audit committee chair.
Martin Andrews (Non-Executive Director)
Martin brings over 30 years of broad commercial experience in pharmaceuticals to Porton Biopharma. He has spent many years in integrative leadership roles at the interface between R&D and commercial disciplines, has led numerous successful product launches, and has deep medicine development and supply chain experience. Most recently, Martin was Senior Vice President of Rare Diseases at GlaxoSmithKline where he had a long career in senior commercial leadership positions in both pharma and vaccines. Under Martin’s leadership, GSK launched the first life-saving gene therapy for children, Strimvelis, and developed a pipeline of ex-vivo gene therapy medicines which were recently acquired by Orchard Therapeutics.
Martin has prior board membership experience at Orchard Therapeutics, Alliance for Regenerative Medicine, and currently serves as non-executive director of Freeline Therapeutics and Evox Therapeutics. Martin is a Biology graduate.